[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582070":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":35,"locations":43,"responsibleParty":60,"collaborators":22,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":22,"enrollmentInfo":72,"targetDuration":22,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":46,"whyStopped":22,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Treatment-Waiting","For this arm, participants receive eight weekly sessions of CBT integrated group treatment in addition to TAU, and then eight weeks of TAU.\n\nThen, 3 months follow-up, receiving TAU.",[12],"Other: TAU+integrated group CBT",{"label":14,"type":6,"description":15,"interventionNames":16},"Waiting-Treatment","For this arm, participants receive eight weeks of TAU, and then eight weekly sessions of CBT integrated group treatment in addition to TAU Then, 3 months follow-up, receiving TAU.",[12],[18],{"type":6,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"TAU+integrated group CBT","TAU+integrated group CBT : participants receive a group psychotherapeutic intervention of Integrated CBT lasting eight weekly two-hour sessions, in parallel with their usual individual care. The sessions are led by a psychologist trained and certified in the practice of CBT and a psychiatrist specialized in addiction medicine. The psychotherapeutic intervention follows a fixed structure and is inspired by the CBT manual for the management of ADHD associated with SUDs published by Matthys et al. (2018). This intervention includes modules on planning and organization, time and distraction management, emotional regulation, work on impulsive behaviors and social skills, cognitive work, as well as substance use management and relapse prevention.\n\nThe sessions will be punctuated by regular breaks to ensure participants' comfort and the integration of the skills worked on during the sessions.\n\nTAU : participants receive their usual care, in exception of group psychotherapeutic interventions.",[9,14],null,[24,28,32],{"name":25,"affiliation":26,"role":27},"Norman Therribout, PhD","Paris-Nanterre University, UR-4430 CLIPSYD ; Paris-Cité University, UMR-S-1144 INSERM; Fernand-Widal Hospital AP-HP","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":30,"role":31},"Romain Icick, MD, PhD","Paris-Cité University, UMR-S-1144 INSERM; Fernand-Widal Hospital AP-HP","STUDY_DIRECTOR",{"name":33,"affiliation":34,"role":31},"Lucia Romo, MD, PhD","Paris-Nanterre University, UR-4430 CLIPSYD",[36,40],{"name":25,"role":37,"phone":38,"phoneExt":22,"email":39},"CONTACT","+33140054464","norman.therribout@aphp.fr",{"name":29,"role":37,"phone":41,"phoneExt":22,"email":42},"+33140054275","espace.murger.lrb@aphp.fr",[44],{"facility":45,"status":46,"city":47,"state":22,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Hôpital Fernand Widal, Assistance-Publique - Hôpitaux de Paris","RECRUITING","Paris","75010","France","FR",{"type":52,"coordinates":53},"Point",[54,55],2.3488,48.85341,{"lat":55,"lon":54},[58],{"name":25,"role":37,"phone":59,"phoneExt":22,"email":39},"+330140054464",{"type":61,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100582070","deficit-hyperactivity-disorder--substance-use-disorder-comorbidity-in-integrated-treatment-100582070",false,"NCT06858527","Deficit Hyperactivity Disorder \u002F Substance Use Disorder Comorbidity in Integrated Treatment","Adults With Attention Deficit Hyperactivity Disorder \u002F Substance Use Disorder Comorbidity in Integrated Treatment: Effectiveness and Feasibility","ATTenTIFF","Inclusion Criteria:\n\n* Age 18 or older ;\n* Suffer from at least one moderate to severe SUD regarding the DSM-5 (tobacco excluded) ;\n* Being currently treated for a SUD by a physician of a psychologist ;\n* Being diagnosed with an ADHD according to the DIVA 2.0 of DIVA-5 ;\n* Being affiliated to a health insurance ;\n* Understanding and being able to express himselves in French\n* Signed consent\n\nExclusion Criteria:\n\n* Age under 18;\n* Pregnant or breastfeeding women;\n* Not having sign the consent form;\n* Major difficulties in understanding and\u002For expressing themselves in french;\n* Severe cognitive impairment;\n* Acute medical condition making assessment impossible and\u002For contraindicating participation in group intervention;\n* Substance use disorder in a protected environment, currentlu or in the last 15 days, or expected during the study;\n* No substance use disorder other than tobacco use disorder;\n* Persons under guardianship;\n* Participant deprived of liberty or under penal care orders;\n* Participation in another group psychotherapeutic intervention throughout the duration of the intervention","ALL","18 Years",{"count":73,"type":74},132,"ESTIMATED","INTERVENTIONAL",[77],"NA","Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs) is a highly common comorbid condition associated with serious medical and psychosocial consequences. However, and despite the international consensus recommending integrated treatment for this comorbidity, few studies tested the efficacy of specific psychotherapeutic treatment for this comorbidity.\n\nThe aim of this study is to test the efficacy of a specific group Cognitive and Behavioral Therapy (CBT) for the treatment of adults with this comorbidity.\n\nThis is a longitudinal, randomized controlled intervention study utilizing a crossover design between the intervention and treatment-as-usual (TAU) waitlist condition, aimed at testing the effectiveness of an integrated psychotherapeutic group treatment for adults with comorbid Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs).",[80,81],"Attention Deficit Hyperactivity Disorder (ADHD)","Substance-related Disorder",[83,84,85,86,87],"Attention Deficit Hyperactivity Disorder","Substance-Related Disorders","Cognitive Behavioral Therapy","Dual Diagnosis","Randomized Controlled Trial","2025-06-23",{"date":90,"type":91},"2025-06-26","ACTUAL",{"date":93,"type":91},"2025-04-01",{"date":95,"type":74},"2029-07",{"name":5,"class":6},1]